Why the study?
Does streptozotocin-induced diabetes alter nitric oxide activity and sensitivity in different sizes of arterioles in rats?
Does streptozotocin-induced diabetes alter nitric oxide activity and sensitivity in different sizes of arterioles in rats?
Answers are grounded in this paper and cite their sources.
Early streptozotocin-induced diabetes in rats causes anatomically specific alterations in microvascular nitric oxide activity and sensitivity that depend on arteriolar size.
Changes in NO activity may play an important role in the early increase in microvascular flow that has been implicated in the pathogenesis of diabetic microangiopathy. We assessed, in the in situ spinotrapezius muscle preparation of 6 weeks' streptozotocin-diabetic rats (n = 6) and of age-matched controls (n = 8), basal inside diameters of A2-A4 arterioles and the reactivity to topically applied acetylcholine and nitroprusside, before and after N(G)-nitro-L-arginine. In diabetic rats, cholinergic vasodilatation in A2-A4 arterioles was intact. Basal diameter in A3 and A4 arterioles was significantly higher in streptozotocin-diabetic rats. The increased basal diameter in A3 arterioles was partially due to an increased contribution of NO to basal diameter. The response to nitroprusside was impaired in streptozotocin-diabetic rats in A2, but not in A3 and A4 arterioles. Thus, this study shows that NO activity and sensitivity are altered after 6 weeks of streptozotocin-induced diabetes. These streptozotocin-induced changes are anatomically specific and, for arterioles, depend on their position within the vascular tree.
No takes yet. Share an insight, caveat, or question.
vanDam et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: